28th Jul 2005 12:45
Results of the Extraordinary General Meeting held on 27 July 2005At the Extraordinary General Meeting of Shire Pharmaceuticals Group plc ("theCompany") held on 27 July 2005, the following resolution to approve theCompany's acquisition of Transkaryotic Therapies, Inc. (TKT) for approximately$1.6 billion in cash or $37.00 per ordinary share was passed on a show ofhands. The proxy votes received for the meeting are set out below:For Against Abstentions 383,713,047 747,228 73,178 Text of Resolution"That the transaction whereby a wholly-owned subsidiary of ShirePharmaceuticals Group plc will merge with and into Transkaryotic Therapies,Inc. and pursuant to which Shire Pharmaceuticals Group plc will become theowner of record of all the outstanding capital stock in TranskaryoticTherapies, Inc. (the "Acquisition") upon the terms and conditions of theAcquisition summarized in the Circular to Shareholders of the Company dated 27June, 2005, with any amendments, modifications, variations or revisions theretowhich are not of a material nature, be and is hereby approved and the directorsof the Company (or any duly authorized committee thereof) be and are herebyauthorized to do all such things and execute all such agreements and make sucharrangements as may seem to them necessary, expedient or appropriate to giveeffect to the Acquisition."A copy of this resolution has been provided to the Financial Services Authorityfor publication through the document viewing facility.For further information please contact:Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing and marketing products in the areas ofcentral nervous system (CNS), gastrointestinal (GI), and renal diseases. Shirehas operations in the world's key pharmaceutical markets (US, Canada, UK,France, Italy, Spain and Germany) as well as a specialist drug delivery unit inthe US.For further information on Shire, please visit the Company's website: www.shire.com."SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF1995Statements included herein that are not historical facts are forward-lookingstatements. Such forward-looking statements involve a number of risks anduncertainties and are subject to change at any time. In the event such risks oruncertainties materialize, Shire's results could be materially affected. Therisks and uncertainties include, but are not limited to, risks associated withthe inherent uncertainty of pharmaceutical research, product development,manufacturing and commercialization, the impact of competitive products,including, but not limited to, the impact of those on Shire's Attention Deficitand Hyperactivity Disorder (ADHD) franchise, patents, including but not limitedto, legal challenges relating to Shire's ADHD franchise, government regulationand approval, including but not limited to Health Canada's suspension ofADDERALL XR⨠sales in Canada and the expected product approval dates of MTS(METHYPATCH) (ADHD), SPD503 (ADHD), SPD465 (ADHD), SPD476 (ulcerative colitis)and NRP104 (ADHD), including its scheduling classification by the DrugEnforcement Agency in the United States, Shire's ability to benefit from itsacquisition of TKT, Shire's ability to secure new products forcommercialization and/or development and other risks and uncertainties detailedfrom time to time in Shire's filings with the Securities and ExchangeCommission, including its Annual Report on Form 10-K for the year to December31, 2004. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire